PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Genedata

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Genedata Provides Biomarker Discovery Platform to Asubio Pharma - Daiichi Sankyo subsidiary Asubio Pharma chooses Genedata to manage DNA array and molecular profiling data
Genedata Provides Biomarker Discovery Platform to Asubio Pharma


NewswireToday - /newswire/ - Basel, Switzerland, 2009/05/18 - Daiichi Sankyo subsidiary Asubio Pharma chooses Genedata to manage DNA array and molecular profiling data.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced that Asubio Pharma, a wholly-owned subsidiary of Daiichi Sankyo Co., Ltd, is using the Genedata Expressionist® system to support their compound profiling and biomarker discovery process.

"We were looking for a bioinformatics solution to manage a huge volume of DNA array data generated internally at Asubio as well as to integrate additional external molecular profiling data,” said Dr. Michinori Kadokura, Associate Senior Researcher at Asubio Pharma. “After a thorough market evaluation, we chose Genedata Expressionist because the system allows us to easily manage large volumes of data in a high-throughput manner and gives bioinformaticians across the company centralized access for data sharing. Furthermore, we are interested in cross-omics analysis which is uniquely supported by Expressionist.”

The Expressionist module Analyst is being used at Asubio Pharma as an ultra high-throughput framework for integrated statistical analysis for biomarker discovery. Analyst features top-tier statistical algorithms, intuitive visualizers and unique technology to integratively analyze data from different omics technologies. Powered by a flexible workflow system and designed to analyze over one billion data points in real-time, Analyst can accommodate both in-house and public domain algorithms for statistical analysis.

“We are very excited to be working with Asubio Pharma, a highly innovative Japanese pharmaceutical company,” commented Dr. Othmar Pfannes, CEO of Genedata. “The Japanese life science market plays an important role in Genedata’s growth strategy. Led by the Genedata Tokyo office, we have been able to rapidly provide innovative solutions to a large number of pharmaceutical and biotechnology companies in Asia.”

About Asubio Pharma
Asubio Pharma ( is a wholly owned subsidiary of Daiichi Sankyo Co., Ltd, dedicated to healing illness and alleviating the pain of patients all over the world by providing superior pharmaceuticals and medical services, based on advanced scientific research and in strict accordance with ethics and rational economics. We focus on new drug discovery through in-house efforts while taking full advantage of the global development capabilities and technology platforms of the Daiichi Sankyo Group and continue our commitment to enhance the quality of life around the world by creating safe and effective drugs that fill unmet therapeutic needs. Achievements to date include the in-house development of Sunrythm®, HANP® and three other new drugs on the market.

About Genedata
Genedata ( develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Genedata


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Genedata Provides Biomarker Discovery Platform to Asubio Pharma

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Allison Kurz - 
+41 61 511 8459 communications[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Genedata securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Genedata / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  NAKIVO, Inc.

Visit  MagLar, Inc.

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (